Literature DB >> 21502563

New take on the role of angiotensin II in cardiac hypertrophy and fibrosis.

Mazen Kurdi1, George W Booz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21502563      PMCID： PMC3098302          DOI： 10.1161/HYPERTENSIONAHA.111.172700

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  38 in total

1.  Prognostic significance of blood pressure and heart rate variabilities: the Ohasama study.

Authors:  M Kikuya; A Hozawa; T Ohokubo; I Tsuji; M Michimata; M Matsubara; M Ota; K Nagai; T Araki; H Satoh; S Ito; S Hisamichi; Y Imai
Journal:  Hypertension       Date:  2000-11       Impact factor: 10.190

2.  Dietary sodium, aldosterone, and left ventricular mass changes during long-term inhibition of the renin-angiotensin system.

Authors:  Guilhem du Cailar; Pierre Fesler; Jean Ribstein; Albert Mimran
Journal:  Hypertension       Date:  2010-10-04       Impact factor: 10.190

3.  Cardiac angiotensin II: does it have a function?

Authors:  A H Jan Danser
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-09-10       Impact factor: 4.733

4.  C-reactive protein and cardiovascular disease: differences between humans and mice.

Authors:  Jørgen Jeppesen; Camilla Asferg
Journal:  Hypertension       Date:  2010-05-17       Impact factor: 10.190

Review 5.  Putting the brakes on cardiac hypertrophy: exploiting the NO-cGMP counter-regulatory system.

Authors:  George W Booz
Journal:  Hypertension       Date:  2005-02-14       Impact factor: 10.190

6.  Novel drugs targeting hypertension revisited.

Authors:  George W Booz
Journal:  J Cardiovasc Pharmacol       Date:  2010-09       Impact factor: 3.105

Review 7.  NAD(P)H oxidase: role in cardiovascular biology and disease.

Authors:  K K Griendling; D Sorescu; M Ushio-Fukai
Journal:  Circ Res       Date:  2000-03-17       Impact factor: 17.367

8.  Up-regulation of p27(kip1) contributes to Nrf2-mediated protection against angiotensin II-induced cardiac hypertrophy.

Authors:  Jinqing Li; Cheng Zhang; Yifan Xing; Joseph S Janicki; Masayuki Yamamoto; Xing Li Wang; Dong-Qi Tang; Taixing Cui
Journal:  Cardiovasc Res       Date:  2011-01-18       Impact factor: 10.787

9.  Heparin cofactor II protects against angiotensin II-induced cardiac remodeling via attenuation of oxidative stress in mice.

Authors:  Yuka Sumitomo-Ueda; Ken-Ichi Aihara; Takayuki Ise; Sumiko Yoshida; Yasumasa Ikeda; Ryoko Uemoto; Shusuke Yagi; Takashi Iwase; Kazue Ishikawa; Yoichiro Hirata; Masashi Akaike; Masataka Sata; Shigeaki Kato; Toshio Matsumoto
Journal:  Hypertension       Date:  2010-07-26       Impact factor: 10.190

10.  Hypertension augments cardiac Toll-like receptor 4 expression and activity.

Authors:  Ruth Eissler; Christoph Schmaderer; Krisztina Rusai; Louisa Kühne; Daniel Sollinger; Tobias Lahmer; Oliver Witzke; Jens Lutz; Uwe Heemann; Marcus Baumann
Journal:  Hypertens Res       Date:  2011-01-20       Impact factor: 3.872
View more
  32 in total

Review 1.  Intracardiac intracellular angiotensin system in diabetes.

Authors:  Rajesh Kumar; Qian Chen Yong; Candice M Thomas; Kenneth M Baker
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-12-14       Impact factor: 3.619

2.  Angiotensin Ⅱ Activates MCP-1 and Induces Cardiac Hypertrophy and Dysfunction via Toll-like Receptor 4.

Authors:  Susumu Matsuda; Seiji Umemoto; Koichi Yoshimura; Shinichi Itoh; Tomoaki Murata; Tohru Fukai; Masunori Matsuzaki
Journal:  J Atheroscler Thromb       Date:  2015-03-05       Impact factor: 4.928

3.  Arjunolic acid, a peroxisome proliferator-activated receptor α agonist, regresses cardiac fibrosis by inhibiting non-canonical TGF-β signaling.

Authors:  Trisha Bansal; Emeli Chatterjee; Jasdeep Singh; Arjun Ray; Bishwajit Kundu; V Thankamani; Shantanu Sengupta; Sagartirtha Sarkar
Journal:  J Biol Chem       Date:  2017-08-18       Impact factor: 5.157

4.  TLR4 regulates vascular smooth muscle cell proliferation in hypertension via modulation of the NLRP3 inflammasome.

Authors:  Hui-Meng Qi; Qin Cao; Qiang Liu
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

5.  Mitochondria and Oxidative Stress in the Cardiorenal Metabolic Syndrome.

Authors:  Annayya R Aroor; Chirag Mandavia; Jun Ren; James R Sowers; Lakshmi Pulakat
Journal:  Cardiorenal Med       Date:  2012-02-07       Impact factor: 2.041

6.  Melatonin attenuates angiotensin II-induced cardiomyocyte hypertrophy through the CyPA/CD147 signaling pathway.

Authors:  Hongyan Su; Jingyuan Li; Tongshuai Chen; Na Li; Jie Xiao; Shujian Wang; Xiaobin Guo; Yi Yang; Peili Bu
Journal:  Mol Cell Biochem       Date:  2016-09-02       Impact factor: 3.396

Review 7.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

8.  Polydatin prevents angiotensin II-induced cardiac hypertrophy and myocardial superoxide generation.

Authors:  Qi Zhang; Yingying Tan; Nan Zhang; Fanrong Yao
Journal:  Exp Biol Med (Maywood)       Date:  2014-12-07

9.  Inactivation of the E-prostanoid 3 receptor attenuates the angiotensin II pressor response via decreasing arterial contractility.

Authors:  Lihong Chen; Yifei Miao; Yahua Zhang; Dou Dou; Limei Liu; Xiaoyu Tian; Guangrui Yang; Dan Pu; Xiaoyan Zhang; Jihong Kang; Yuansheng Gao; Shiqiang Wang; Matthew D Breyer; Nanping Wang; Yi Zhu; Yu Huang; Richard M Breyer; Youfei Guan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-10-11       Impact factor: 8.311

10.  Ets-1 upregulation mediates angiotensin II-related cardiac fibrosis.

Authors:  Guanghua Hao; Zhenhua Han; Zhe Meng; Jin Wei; Dengfeng Gao; Hong Zhang; Nanping Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.